Market access

Results: 1 - 9 of 10
view
CGT Catapult hosts second annual workshop to address digital challenges in adoption of advanced therapies by the NHS

Experts addressed different possible models for optimising data collection to support the...

Read more
view
A framework for quantifying digital infrastructure upgrade costs in order to address data needs of outcomes-based reimbursement
Read more
view
Enabling outcomes-based reimbursement through a universal platform for outcomes data

How do you prove the lifetime benefits of a potentially life-altering one-off therapy through...

Read more
view
To what extent can the EBMT registry enable outcomes-based reimbursement in oncology in the UK?

In previous work, we have shown that outcomes-based reimbursement (OBR), whereby payments to...

Read more
view
To what extent can the SACT database enable outcomes-based reimbursement in oncology in England?

In previous work, we have shown that outcomes-based reimbursement (OBR), whereby payments to...

Read more
view
Quantifying the cost of implementing an outcomes-based managed entry agreement in acute lymphoblastic leukaemia (ALL)

Outcomes-based managed entry agreements (MEAs) can enable patient access to promising high cost...

Read more
view
Identifying the price and access potential of a novel ATMP in the United States

The HE&MA function of the CGT Catapult engaged with an ATMP developer to identify the US...

Read more
view
Enabling a valuable engagement with EMA and HTA bodies as part of the Parallel Consultation procedure

A key challenge for the commercial viability of ATMPs is achieving both a high price and...

Read more
view
Health economics and market access

Understanding how price, revenue and profit margins can be maximised is key to any commercial...

Read more
  • RT : I am delighted to announce new Life Science Opportunity Zones which will boost this important thriving sector. The… https://t.co/4aKZVaZqgE — 1 day 9 hours ago

Discover who we are

 
Sign up